Drugs / ENOKIZUMAB
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00116168 | Jun 2005 → Apr 2006 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00192296 | Aug 2004 → Feb 2005 | asthma | MedImmune LLC | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT00968669 | Dec 2009 → Nov 2011 | asthma | MedImmune LLC | Completed | Missed primary |
| Phase 2 | NCT00590720 | Mar → Dec 2008 | asthma | MedImmune LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00483041 | Jul 2007 → Oct 2008 | asthma | MedImmune LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00507130 | Jul 2007 → Jul 2008 | asthma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00394654 | Nov 2006 → Aug 2007 | asthma | MedImmune LLC | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENOKIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743012 ↗ |
| Known as | 7F3COM-2H2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743012 ↗ |
| Known as | MEDI-528 | “Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in...” PMID 21356110 ↗ Feb 20115“The aim of this study was therefore to evaluate the effects of MEDI-528, an anti-interleukin-9 monoclonal antibody, in adults with confirmed uncontrolled moderate-to-severe asthma.” PMID 24050312 ↗ Sep 2013 “MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion” NCT00483041 ↗ |
| Action | Inhibit | “inhibition of IL-9 through neutralizing monoclonal antibody (mAb) treatment” PMID 19446146 ↗ Apr 2009 |
| Modality | Monoclonal antibody | “MEDI-528, a monoclonal antibody against interleukin-9” PMID 19446146 ↗ Apr 2009 |
| Route | Subcutaneous | “by subcutaneous injection” PMID 19446146 ↗ Apr 2009 |
| Target | IL9 | “MEDI-528, a humanized immunoglobulin G1k anti-IL-9 mAb” PMID 19446146 ↗ Apr 2009 |